211 related articles for article (PubMed ID: 30669852)
1. Effect of Alprostadil on the Prevention of Contrast-Induced Nephropathy: A Meta-Analysis of 36 Randomized Controlled Trials.
Xie J; Jiang M; Lin Y; Deng H; Li L
Angiology; 2019 Aug; 70(7):594-612. PubMed ID: 30669852
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of alprostadil in preventing contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: A multicenter prospective randomized controlled trial.
Liang M; Yang S; Fu N; Lu C; Tian F; Xing X; Lin W; Liu J
Catheter Cardiovasc Interv; 2018 Mar; 91(4):742-750. PubMed ID: 29024304
[TBL] [Abstract][Full Text] [Related]
3. Preprocedure and Postprocedure Predictive Values of Serum β2-Microglobulin for Contrast-Induced Nephropathy in Patients Undergoing Coronary Computed Tomography Angiography: A Comparison With Creatinine-Based Parameters and Cystatin C.
Li S; Zheng Z; Tang X; Peng L; Luo Y; Dong R; Zhao Y; Liu J
J Comput Assist Tomogr; 2015; 39(6):969-74. PubMed ID: 26248154
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of nicorandil treatment for prevention of contrast-induced nephropathy in high-risk patients undergoing cardiac catheterization: A prospective randomized controlled trial.
Iranirad L; Hejazi SF; Sadeghi MS; Jang SA
Cardiol J; 2017; 24(5):502-507. PubMed ID: 28281738
[TBL] [Abstract][Full Text] [Related]
5. Preventive effect of oral nicorandil on contrast-induced nephropathy in patients with renal insufficiency undergoing elective cardiac catheterization.
Fan Y; Wei Q; Cai J; Shi Y; Zhang Y; Yao L; Wang X; Lin S; Li Y; Lv J; Zhou B; Du R
Heart Vessels; 2016 Nov; 31(11):1776-1782. PubMed ID: 26874946
[TBL] [Abstract][Full Text] [Related]
6. The effect of alprostadil on preventing contrast-induced nephropathy for percutaneous coronary intervention in diabetic patients: A systematic review and meta-analysis.
Ye Z; Lu H; Guo W; Dai W; Li H; Yang H; Li L
Medicine (Baltimore); 2016 Nov; 95(46):e5306. PubMed ID: 27861357
[TBL] [Abstract][Full Text] [Related]
7. Insulin Resistance Increases the Risk of Contrast-Induced Nephropathy in Patients Undergoing Elective Coronary Intervention.
Li Y; Liu Y; Shi D; Yang L; Liang J; Zhou Y
Angiology; 2016 Feb; 67(2):139-45. PubMed ID: 25843952
[TBL] [Abstract][Full Text] [Related]
8. CHA2DS2-VASC score as a preprocedural predictor of contrast-induced nephropathy among patients with chronic total occlusion undergoing percutaneous coronary intervention: a single-center experience.
Wang Y; Zhao HW; Zhang XJ; Chen BJ; Yu GN; Hou AJ; Luan B
BMC Cardiovasc Disord; 2019 Mar; 19(1):74. PubMed ID: 30922230
[TBL] [Abstract][Full Text] [Related]
9. The influence of contrast media on kidney function in patients with stable coronary artery disease.
Reuter SB; Harutyunyan M; Mygind ND; Jørgensen E; Kastrup J
Scand Cardiovasc J; 2014 Aug; 48(4):234-40. PubMed ID: 24941300
[TBL] [Abstract][Full Text] [Related]
10. Age, glomerular filtration rate, ejection fraction, and the AGEF score predict contrast-induced nephropathy in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
Andò G; Morabito G; de Gregorio C; Trio O; Saporito F; Oreto G
Catheter Cardiovasc Interv; 2013 Nov; 82(6):878-85. PubMed ID: 23703775
[TBL] [Abstract][Full Text] [Related]
11. The Preventive Effect of Alprostadil on the Contrast-Induced Nephropathy of Coronary Heart Disease Treated by Percutaneous Coronary Intervention in Moderate and High-Risk Population Stratified by Mehran Score.
Liu X; Zhang P; Zhang J; Zhang X; Yang S; Fu N
Angiology; 2022 Jan; 73(1):33-41. PubMed ID: 34098771
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study.
Fu N; Yang S; Zhang J; Zhang P; Liang M; Cong H; Lin W; Tian F; Lu C
Int Urol Nephrol; 2018 Jan; 50(1):105-112. PubMed ID: 29071556
[TBL] [Abstract][Full Text] [Related]
13. Alprostadil plays a protective role in contrast-induced nephropathy in the elderly.
Miao Y; Zhong Y; Yan H; Li W; Wang BY; Jin J
Int Urol Nephrol; 2013 Aug; 45(4):1179-85. PubMed ID: 23860961
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of theophylline in preventing contrast-induced nephropathy after coronary angiographic procedures.
Bilasy ME; Oraby MA; Ismail HM; Maklady FA
J Interv Cardiol; 2012 Aug; 25(4):404-10. PubMed ID: 22612071
[TBL] [Abstract][Full Text] [Related]
15. Predictive Value of Hepatorenal Status in Contrast-Induced Nephropathy Among Patients Receiving Coronary Angiography and/or Intervention: A Systematic Review and Meta-Analysis.
Zhang E; Lu Y; Chen G; Huang L; Zhang J; Wang C; Qin Q
Angiology; 2019 Aug; 70(7):633-641. PubMed ID: 30525915
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Alprostadil in Preventing Contrast-Induced Nephropathy: A Systematic Review and Meta-Analysis.
Xu H; Wang H; Zhang C; Xiao J; Hua N; Tang X; Xie J; Zhang Z
Angiology; 2021 Oct; 72(9):878-888. PubMed ID: 33853365
[TBL] [Abstract][Full Text] [Related]
17. Alprostadil protects type 2 diabetes mellitus patients treated with metformin from contrast-induced nephropathy.
Wang J; Ai X; Li L; Gao Y; Sun N; Li C; Sun W
Int Urol Nephrol; 2017 Nov; 49(11):2019-2026. PubMed ID: 28656510
[TBL] [Abstract][Full Text] [Related]
18. Brain natriuretic peptide for prevention of contrast-induced nephropathy after percutaneous coronary intervention or coronary angiography.
Liu JM; Xie YN; Gao ZH; Zu XG; Li YJ; Hao YM; Chang L
Can J Cardiol; 2014 Dec; 30(12):1607-12. PubMed ID: 25418218
[TBL] [Abstract][Full Text] [Related]
19. Preventive Effects of Alprostadil Against Contrast-Induced Nephropathy Inpatients With Renal Insufficiency Undergoing Percutaneous Coronary Intervention.
Yang SC; Fu NK; Zhang J; Liang M; Cong HL; Lin WH; Tian FS; Lu CZ; Sun TT; Zhang WY; Ma ZH
Angiology; 2018 May; 69(5):393-399. PubMed ID: 29073785
[TBL] [Abstract][Full Text] [Related]
20. Effects of intravenous hydration on risk of contrast induced nephropathy and in-hospital mortality in STEMI patients undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials.
Liu Y; Hong D; Wang AY; Guo R; Smyth B; Liu J; Sun G; Chen S; Tan N; Jardine M; Brieger D; Shaman A; Islam S; Chen J; Gallagher M
BMC Cardiovasc Disord; 2019 Apr; 19(1):87. PubMed ID: 30961544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
